Please login to the form below

Not currently logged in
Email:
Password:

Eli Lilly

This page shows the latest Eli Lilly news and features for those working in and with pharma, biotech and healthcare.

UCB’s bimekizumab beats AbbVie’s Humira in phase 3 trial

UCB’s bimekizumab beats AbbVie’s Humira in phase 3 trial

This includes a new class of JAK inhibitors, such as AbbVie’s Rinvoq (upadacitinib), Pfizer’s Xeljanz (tofacitinib) and Eli Lilly’s Olumiant (baricitinib).

Latest news

More from news
Approximately 91 fully matching, plus 594 partially matching documents found.

Latest Intelligence

  • Detecting Alzheimer’s ahead of a cure Detecting Alzheimer’s ahead of a cure

    Digital detection. One such promising study comes from Eli Lilly, in partnership with Apple and Evidation Health. ... According to Divakar Ramakrishnan, Lilly’s chief digital officer, the findings from this study “could inform subsequent research

  • The fight for affordable insulin The fight for affordable insulin

    The world’s three biggest insulin manufacturers are Novo Nordisk, Sanofi and Eli Lilly. ... Lilly’s authorised generic. One company, Eli Lilly, has responded to the pleas for more affordable insulins, and launched a half price ‘authorised

  • Where next in Alzheimer’s disease R&D? Where next in Alzheimer’s disease R&D?

    Since 2012, AC Immune has partnered tau assets with Roche’s Genentech, Johnson &Johnson and Eli Lilly. ... Sosei Heptares’ work on M1 falls into the latter category. Eli Lilly took an M1 agonist, xanomeline, into phase 3 in the 1990s and emerged with

  • Brain power: fresh approaches to Alzheimer’s drug discovery Brain power: fresh approaches to Alzheimer’s drug discovery

    EPAD combines knowledge and expertise from 39 European partner organisations across multiple sectors, including most of the big pharma companies involved in Alzheimer’s research (including Amgen, Janssen and Lilly, among ... Last month, Johnson

  • The handover: Pfizer reshapes itself for a new era The handover: Pfizer reshapes itself for a new era

    Developed in partnership with Eli Lilly, it has already presented positive phase 3 results, with more expected in the first half of 2019, with filings expected shortly afterwards.

More from intelligence
Approximately 4 fully matching, plus 29 partially matching documents found.

Latest appointments

More from appointments
Approximately 6 fully matching, plus 30 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 1 fully matching, plus 18 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OUTiCO

Providing an exceptional outsourcing service to the Pharma & Healthcare industries. We offer a sustainable approach and drive sales outcomes...

Latest intelligence

Five key trends in precision and personalised healthcare
Here, we deep dive into five of the key trends in precision medicine and personalised healthcare to explore how the healthcare industry is changing and how pharmaceutical and biotech companies...
OPEN Health Graduate Programme: from OPEN VIE to OPEN Health Medical Communications
Isobel Owens shares her experience of the OPEN Health Graduate Programme from OPEN VIE to OPEN Health Medical Communications...
Language barriers: Obesity has become a loaded word
...

Infographics